ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis €0.13 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Medigene Stock (ETR:MDG1) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medigene alerts:Sign Up Key Stats Today's Range€0.13▼€0.1350-Day Range€0.13▼€0.1352-Week Range€1.60▼€5.51VolumeN/AAverage Volume306,207 shsMarket Capitalization€1.02 millionP/E RatioN/ADividend Yield1.31%Price TargetN/AConsensus RatingN/A Company Overview Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany. Read More Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address MDG1 Stock News HeadlinesMedigene verlässt Prime Standard wegen InsolvenzverfahrenJune 13, 2025 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG hat Eröffnung des Insolvenzverfahrens beantragt - Einberufung zur aoHV nach §92 AktG entfälltApril 29, 2025 | finanznachrichten.deThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 14 at 2:00 AM | Brownstone Research (Ad)PTA-Adhoc: Medigene AG: Medigene AG stellt Antrag auf Eröffnung eines InsolvenzverfahrensApril 7, 2025 | finanznachrichten.deMedigene Files Patent for Unique NK-Specific TCR Construct with European Patent OfficeMarch 13, 2025 | markets.businessinsider.comMedigene and EpimAb to develop T cell engagers for solid tumoursFebruary 28, 2025 | finance.yahoo.comPTA-News: Medigene AG: Medigene und EpimAb Biotherapeutics schließen Co-Entwicklungspartnerschaft für TCR-gesteuerte T-Zell-Engager abFebruary 27, 2025 | finanznachrichten.deMedigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell EngagersFebruary 27, 2025 | markets.businessinsider.comSee More Headlines MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed this year? Medigene's stock was trading at €1.03 at the beginning of the year. Since then, MDG1 stock has decreased by 87.0% and is now trading at €0.13. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income-€4.67 million Net Margins-249.83% Pretax MarginN/A Return on Equity-80.38% Return on Assets-27.15% Debt Debt-to-Equity Ratio12.95 Current Ratio2.39 Quick Ratio5.85 Sales & Book Value Annual Sales€1.87 million Price / Sales0.54 Cash Flow€0.10 per share Price / Cash Flow1.37 Book Value€0.72 per share Price / Book0.18Miscellaneous Outstanding Shares7,619,243Free FloatN/AMarket Cap€1.02 million OptionableNot Optionable Beta0.84 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (ETR:MDG1) was last updated on 7/14/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredIt’s game over when Elon rolls this outElon Musk says his upcoming innovation could be the "biggest product of all time"... And by the looks of th...InvestorPlace | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.